Established in 2008, Therapeutic Innovation Australia (TIA) is the lead agent for the National Collaborative Research Infrastructure Strategy (NCRIS) “Therapeutic Innovation Australia” project funded by the Australian Department of Education.
TIA supports national research infrastructure across four capabilities :
• Biologics & Vaccines
• Cell & Gene Therapies
• Small Molecule Therapeutics
• RNA Products
We have developed a Strategic Plan for the period 2023-2028 that outlines key strategic aims associated with support of a network of Australian translational research infrastructure.
For the Australian research community to have access to world class research infrastructure to enable efficient translation of therapeutics to improve human health.
TIA will enable and accelerate the translation of research discovery along the therapeutic development pipeline by investing in world class research infrastructure facilities so they are coordinated, comprehensive, accessible and responsive to the needs of the Australian translational research community.
TIA Ltd is a not-for-profit company limited by guarantee, and is governed by applicable legislation. TIA is overseen by an independent, skills-based Board that meets monthly, and a Governance, Audit and Risk Committee chaired by the Company Secretary that meets every two months. The Board members are knowledgable individuals with extensive experience in the public, private and not-for-profit sectors.
Mr Terry Slater AM
BSc, BEc, MPH, MAICD, FAIM
Prof Judith Whitworth AC
MBBS, MD, PhD, DSc (Melb),HonDSc (Glasgow), FRACP, FAICD, FTSE, FAHMS (hon), MD (hon), Syd, MD (hon) UNSW, D Lett (hon) CDU, LD (hon) Melb
Mr Rob Anderson
Prof Ross McKinnon
B Pharm, B Sci (Hons), PhD, FFIP, FGLF, FAHMS, MAICD Director
TIA’s management consists of a CEO and a Director of Programs, supported by a Scientific Advisor to the Board and a Board Secretary.
Dr Stuart Newman
Chief Executive Officer
Dr MJ Chua
Director of Programs
A/Prof Stella Clark AM
Scientific Adviser to the Board
Melbourne Office Manager and Board Secretary
TIA provides support to the sector via a scientific engagement team. These experts in their field are tasked with helping to build and maintain the network of TIA capabilities, as well as provide promotion and referral to TIA facilities.
Mr Ben Hughes
Director of Strategic Development, National Biologics Facility
Dr Heather Donaghy
Scientific Engagement Manager, Cell & Gene Therapies
Dr John Parisot
Business Development Manager, Small Molecule Therapeutics
TIA Values Diversity and Equity
Life science and biomedical research enjoys a more favourable gender balance and diversity profile than many other sectors, but as roles become more senior this balance markedly shifts to favour men over women and marginalised groups.
As a source of funding for employment of biomedical research support and technical staff, TIA takes seriously its responsibility to contribute to an appropriate gender balance and a culture of inclusion at all levels of seniority across the sector.
TIA’s staff and Board abide by the following principles:
This pledge is made with the endorsement of the Board and Staff of Therapeutic Innovation Australia Ltd
This pledge is adapted from material from the Champions of Change coalition website. TIA has provided staff with guidance on responding to requests to speak at public events to courteously ask questions on the diversity and gender balance of the panel or program.
Please contact us to discuss this pledge or other issues of equity and diversity relating to biomedical and life sciences research.